Key Takeaways
- Defence Therapeutics has appointed Dr. Amie Phinney as Strategy & Business Advisor to enhance its strategic direction.
- Dr. Phinney brings over 20 years of experience in biotech and pharmaceutical sectors, having held leadership roles at major companies.
- The company’s ACCUM® technology aims to improve cancer treatment efficacy through precise delivery of antibody-drug conjugates.
New Strategic Appointment at Defence Therapeutics
Defence Therapeutics Inc. (OTCQB: DTCFF) has announced the immediate appointment of Dr. Amie Phinney as Strategy & Business Advisor. Her role will focus on refining the company’s strategic plans to leverage new scientific advancements for future growth.
Dr. Phinney is a well-respected expert in life sciences commercialization, boasting over 20 years in pharmaceutical R&D and biotech innovation. Her resume includes significant positions at Abbott and AbbVie, where she led strategic collaborations and global R&D efforts. Additionally, she served as Chief Scientific Officer for Lakeside Discovery, facilitating early-stage therapeutic programs. Most recently, Dr. Phinney was Senior Director of Partnerships at adMare BioInnovations, where she helped foster biotech ventures from Canadian academic institutions.
Commenting on the appointment, Sébastien Plouffe, founder and CEO of Defence Therapeutics, emphasized that the company is at a crucial junction, with its innovative science creating unique opportunities. He expressed confidence that Dr. Phinney’s extensive track record in both established pharmaceutical firms and start-ups would help position Defence Therapeutics for sustainable growth.
Dr. Phinney also conveyed her enthusiasm for joining Defence Therapeutics, citing the groundbreaking nature of its research in antibody-delivered therapeutics. She looks forward to collaborating with the leadership team to develop a roadmap that translates scientific discoveries into impactful innovations for patients and stakeholders.
Dr. Phinney holds a PhD in Biomedical Research from the University of Basel and an MBA from Lake Forest Graduate School of Management. Her executive training spans governance, private investment, and leadership from esteemed institutions, including the University of Toronto and Northwestern University.
Defence Therapeutics is recognized as a clinical-stage biotechnology entity focused on developing the next generation of antibody-drug conjugates (ADCs) through its proprietary ACCUM® technology. This platform aims to facilitate the precise delivery of ADCs to target cells, thus enhancing treatment efficacy against cancer.
Investors are reminded that this release contains forward-looking statements based on management’s beliefs and expectations, which are not guarantees of future performance. Factors such as regulatory actions and market conditions could impact the actual results, which may differ from projected expectations.
For additional information, visit www.defencetherapeutics.com.
The content above is a summary. For more details, see the source article.